Log in

Achieve Life Sciences Stock Forecast, Price & News

+0.15 (+1.62 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $9.43
50-Day Range
MA: $9.04
52-Week Range
Now: $9.43
Volume116,815 shs
Average Volume248,182 shs
Market Capitalization$33.83 million
P/E RatioN/A
Dividend YieldN/A
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Read More
Achieve Life Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:ACHV



Sales & Book Value

Annual SalesN/A
Book Value$12.24 per share


Net Income$-16,400,000.00


Market Cap$33.83 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
+0.15 (+1.62 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACHV News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions

How has Achieve Life Sciences' stock been impacted by COVID-19 (Coronavirus)?

Achieve Life Sciences' stock was trading at $8.3240 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ACHV stock has increased by 13.3% and is now trading at $9.43.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Achieve Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Achieve Life Sciences

When is Achieve Life Sciences' next earnings date?

Achieve Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Achieve Life Sciences

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences Inc (NASDAQ:ACHV) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.68) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($3.80) by $2.12.
View Achieve Life Sciences' earnings history

When did Achieve Life Sciences' stock split? How did Achieve Life Sciences' stock split work?

Achieve Life Sciences shares reverse split before market open on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ACHV?

4 brokerages have issued 1 year price objectives for Achieve Life Sciences' shares. Their forecasts range from $21.00 to $100.00. On average, they expect Achieve Life Sciences' stock price to reach $47.75 in the next year. This suggests a possible upside of 406.4% from the stock's current price.
View analysts' price targets for Achieve Life Sciences

Are investors shorting Achieve Life Sciences?

Achieve Life Sciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 505,500 shares, an increase of 25.8% from the August 15th total of 401,800 shares. Based on an average daily volume of 524,900 shares, the short-interest ratio is currently 1.0 days. Currently, 22.1% of the shares of the stock are sold short.
View Achieve Life Sciences' Short Interest

Who are some of Achieve Life Sciences' key competitors?

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Novan (NOVN), AEterna Zentaris (AEZS), BioNano Genomics (BNGO), Zosano Pharma (ZSAN), Cannabics Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania R.E.I.T. (PEI).

Who are Achieve Life Sciences' key executives?

Achieve Life Sciences' management team includes the following people:
  • Dr. Richard A. B. Stewart, Chairman & CEO (Age 60)
  • Dr. Anthony Clarke, Pres, Chief Scientific Officer & Director (Age 63)
  • Mr. John A. Bencich, Exec. VP, CFO & COO (Age 42)
  • Dr. Cindy Jacobs, Exec. VP & Chief Medical Officer (Age 61)
  • Ms. Jaime Xinos, Exec. VP of Commercial

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ikarian Capital LLC (233.33%), Requisite Capital Management LLC (63.78%) and UBS Group AG (0.29%). Company insiders that own Achieve Life Sciences stock include Armistice Capital Master Fund and Richard Alistair Stewart.
View institutional ownership trends for Achieve Life Sciences

Which major investors are buying Achieve Life Sciences stock?

ACHV stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Requisite Capital Management LLC, and UBS Group AG. Company insiders that have bought Achieve Life Sciences stock in the last two years include Armistice Capital Master Fund, and Richard Alistair Stewart.
View insider buying and selling activity for Achieve Life Sciences

How do I buy shares of Achieve Life Sciences?

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $9.43.

How big of a company is Achieve Life Sciences?

Achieve Life Sciences has a market capitalization of $33.83 million. The biopharmaceutical company earns $-16,400,000.00 in net income (profit) each year or ($39.80) on an earnings per share basis. Achieve Life Sciences employs 13 workers across the globe.

What is Achieve Life Sciences' official website?

The official website for Achieve Life Sciences is achievelifesciences.com.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.